SCHEMBL3964524

SCHEMBL3964524

Cn1cc(C2(Cc3cccc(Cl)c3)C(=O)Nc3cc(Cl)ccc32)cn1

nearest known ligand 0.62

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
MDM2 Q00987 11/20 0.62
TP53 P04637 10/20 0.62
EPHX2 P34913 1/20 0.41
LMNA P02545 1/20 0.40
GHSR Q92847 1/20 0.37
MAOB P27338 1/20 0.37
PGR P06401 1/20 0.37
ALDH1A1 P00352 1/20 0.37
FSCN1 Q16658 1/20 0.36
AKR1B1 P15121 1/20 0.36
MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3967431 0.80 MDM2 (0.66) MDM2TP53MAOBPGR
SCHEMBL3969840 0.78 MDM2 (0.70) MDM2TP53GHSRMAOBPGR
SCHEMBL3964516 0.78 MDM2 (0.67) MDM2TP53GHSRMAOBPGR
SCHEMBL3970206 0.78 MDM2 (0.66) MDM2TP53MAOBPGRALDH1A1
SCHEMBL3969641 0.78 MDM2 (0.86) MDM2TP53MAOBPGR
SCHEMBL3968096 0.77 MDM2 (1.00) MDM2TP53MAOBPGR
SCHEMBL3968099 0.77 MDM2 (1.00) MDM2TP53MAOBPGR
SCHEMBL3969747 0.76 MDM2 (0.70) MDM2TP53MAOBPGRALDH1A1
SCHEMBL3968966 0.76 MDM2 (0.70) MDM2TP53MAOBPGR
SCHEMBL3973098 0.75 IDO1 (0.42) MDM2GHSRAKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576082-B2 Oxindole derivatives HOFFMAN-LA ROCHE INC. (US) 2009-08-18 US claimed
JP-2008543917-A 2008-12-04 JP claimed
EP-1896412-A2 OXINDOLE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2008-03-12 EP claimed
WO-2006136606-A2 OXINDOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-12-28 WO claimed
US-20060293319-A1 Oxindole derivatives LUK KIM-CHUN 2006-12-28 US claimed
US-7576082-B2 Oxindole derivatives HOFFMAN-LA ROCHE INC. (US) 2009-08-18 US disclosed
US-7576082-B2 Oxindole derivatives HOFFMAN-LA ROCHE INC. (US) 2009-08-18 US disclosed
US-7576082-B2 Oxindole derivatives HOFFMAN-LA ROCHE INC. (US) 2009-08-18 US disclosed
EP-1896412-A2 OXINDOLE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2008-03-12 EP disclosed
WO-2006136606-A2 OXINDOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-12-28 WO disclosed
WO-2006136606-A2 OXINDOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-12-28 WO disclosed
US-20060293319-A1 Oxindole derivatives LUK KIM-CHUN 2006-12-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060293319-A1 Oxindole derivatives CCNI, OGFR, MKI67 MDM2 759/4885TP53 96/4885EPHX2 3479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.